This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects (OC-DDI)

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: October 24, 2007
Last updated: September 12, 2011
Last verified: September 2011
A Phase 1, drug, drug, interaction study between Lurasidone HCl and Ortho-tri cyclen

Condition Intervention Phase
Pharmacokinetics Drug: Lurasidone 40 mg Drug: Placebo 40 mg Drug: Ortho Tri-Cyclen Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Official Title: A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

Resource links provided by NLM:

Further study details as provided by Sunovion:

Enrollment: 23
Study Start Date: August 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lurasidone 40 mg Drug: Lurasidone 40 mg
Lurasidone 40 mg days 12-21 once daily
Placebo Comparator: Placebo Drug: Placebo 40 mg
Placebo 40 mg once daily during treatment period
Active Comparator: Ortho Tri-Cyclen Drug: Ortho Tri-Cyclen
Ortho Tri-Cyclen during 28-day lead in period


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is female between 18 and 40 years of age
  • Female subjects of reproductive potential will demonstrate a negative serum β-human chorionic gonadotropin level consistent with the non-gravid state at the screening visit
  • Subject agrees to take the triphasic oral contraceptive, Ortho Tri-Cyclen™, throughout the study.
  • Subject has a history of regular menstrual periods with no substantial breakthrough bleeding episodes while taking Ortho Tri-Cyclen™.
  • Subject has a body mass index that is < 33 kg/m2 (see Appendix 1).
  • Subject is judged to be in good health
  • Subject must have a negative hepatiti and HIV antibody at screening.
  • Subject has no clinically significant abnormality on screening ECG.

Exclusion Criteria:

  • Subject has a history of major GI abnormalities/peptic ulceration, hematological, genitourinary, cardiovascular (including hypertension), renal, hepatic, pulmonary, psychiatric, endocrine (including diabetes) or metabolic (including glaucoma), neurologic or cerebrovascular disease, or any history of cancer.
  • Subject has systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg at screening.
  • Subject has a history of any chronic and/or active hepatic disease including elevations of serum transaminases, hepatitis, biliary tract disease, or a history of any gastrointestinal surgery.
  • Subject has any other acute or chronic medical or psychiatric condition that, in the opinion of the investigator, would limit the patient safety or confound the results of the study.
  • Subject has an ECG at screening with PR > 240 msec; QRS complex > 120 msec; QTcB > 450; or any significant morphologic changes other than nonspecific T-wave changes.
  • Subject is currently a user of any illicit drugs (including "recreational use") including marijuana, or has recently used illicit drugs, or has a history of drug or alcohol dependence in the past year or abuse within the last 3 months.
  • Subject consumes excessive amounts of alcohol
  • Subject has had surgery within last 12 weeks, donated a unit of blood (within 4 weeks), or participated in another clinical study within 30 days of screening.
  • Subjects with hypertension, hyperlipidemia, and diabetes should also be excluded. (See package circular under "Contraindications")
  • Subject has clinically significant abnormalities at screening clinical examination or laboratory safety tests
  • Subject has a prolactin level of over 200 ng/mL at screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00549666

United States, California
Covance Global Clinical Pharmacology, Inc.
San Diego, California, United States, 92123
Sponsors and Collaborators
Study Director: Medical Director, MD Sunovion
  More Information

Responsible Party: Sunovion Identifier: NCT00549666     History of Changes
Other Study ID Numbers: D1050246
Study First Received: October 24, 2007
Last Updated: September 12, 2011

Keywords provided by Sunovion:

Additional relevant MeSH terms:
Contraceptive Agents
Norgestimate, ethinyl estradiol drug combination
Contraceptives, Oral
Lurasidone Hydrochloride
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Female
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Contraceptives, Oral, Combined
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on September 21, 2017